Publication date: October 2012 | Version: 4 | Pages: 757
Report description
The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter biomarker partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors biomarker technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This report contains over 550 links to online copies of actual biomarker deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of biomarker dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in biomarker dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading biomarker deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of biomarker deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since January 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided organized by biomarker partnering company A-Z , deal type definitions and biomarker partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of biomarker technologies and products.
Key benefits
Biomarker Partnering Terms and Agreements provides the reader with the following key benefits:
• In-depth understanding of biomarker deal trends since 2007
• Access to headline, upfront, milestone and royalty data
• Analysis of the structure of biomarker agreements with numerous real life case studies
• Comprehensive access to over 550 actual biomarker contracts entered into by the world’s biopharma companies
• Detailed access to actual biomarker contracts enter into by the leading fifty bigpharma companies
• Insight into the terms included in a biomarker agreement, together with real world clause examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope
Biomarker Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to biomarker trends and structure of deals entered into by leading companies worldwide.
Biomarker Partnering Terms and Agreements includes:
o Trends in biomarker dealmaking in the biopharma industry since 2007
o Analysis of biomarker deal structure
o Access to headline, upfront, milestone and royalty data
o Case studies of real-life biomarker deals
o Access to over 600 biomarker contract documents
o The leading biomarker deals by value since 2007
o Most active biomarker dealmakers since 2007
o The leading biomarker partnering resources
In Biomarker Partnering Terms and Agreements, the available contracts are listed by:
o Company A-Z
o Headline value
o Stage of development at signing
o Deal component type
o Specific therapy target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Biomarker Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 550 biomarker deals. Analyzing actual contract agreements allows assessment of the following:
o What are the precise biomarker rights granted or optioned?
o What is actually granted by the agreement to the partner company?
o What exclusivity is granted?
o What is the payment structure for the deal?
o How are sales and payments audited?
o What is the deal term?
o How are the key terms of the agreement defined?
o How are IPRs handled and owned?
o Who is responsible for commercialization?
o Who is responsible for development, supply, and manufacture?
o How is confidentiality and publication managed?
o How are disputes to be resolved?
o Under what conditions can the deal be terminated?
o What happens when there is a change of ownership?
o What sublicensing and subcontracting provisions have been agreed?
o Which boilerplate clauses does the company insist upon?
o Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
o Which jurisdiction does the company insist upon for agreement law?
TABLE OF CONTENTS
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in bioinformatics dealmaking
2.1. Introduction
2.2. Biomarker partnering over the years
2.3. Bigpharma biomarker dealmaking activity
2.4. Bigpharma not active in biomarkers
2.5. Biomarker partnering by deal type
2.6. Biomarker partnering by disease type
2.7 Average deal terms for biomarkers
2.7.1 Biomarker headline values
2.7.2 Biomarker upfront payments
2.7.3 Biomarker milestone payments
2.7.4 Biomarker royalty rates
Chapter 3 – Leading biomarker deals
3.1. Introduction
3.2. Top biomarker deals by value
3.3. Top biomarker deals involving bigpharma
Chapter 4 – Bigpharma biomarker deals
4.1. Introduction
4.2. How to use bigpharma biomarker partnering deals
4.3. Bigpharma biomarker partnering company profiles
Abbott
AstraZeneca
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Daiichi Sankyo
Eisai
Eli Lilly
GlaxoSmithKline
Johnson & Johnson
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Pfizer
Roche
Sanofi
Servier
Takeda
Teva
UCB
Chapter 5 – Biomarker dealmaking directory
5.1. Introduction
5.2. By stage of development
Discovery
Marketed
Preclinical
Phase I
Phase II
Phase III
Regulatory
5.3. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Manufacturing - OEM
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
5.4. By therapy area
Cardiovascular
Central Nervous System
Dental
Dermatology
Gastrointestinal
Genetic disorders
Genitourinary
Gynaecology
Hematology
Hospital care
Immunology
Infectives
Metabolic
Musculoskeletal
Obstetrics
Oncology
Ophthalmics
Pediatrics
Psychiatry
Public Health
Respiratory
Sensory Organs
Chapter 6 – Biomarker partnering resource center
6.1. Online biomarker partnering
6.2. Biomarker partnering events
6.3. Further reading on biomarker dealmaking
Appendices
Appendix 1 – Deals by company A-Z
Appendix 2 – Deal type definitions
Appendix 3 – Example biomarker partnering agreement
About Wildwood Ventures
Table of figures
Figure 1: Biomarker partnering since 2007
Figure 2: Bigpharma – top 50 – biomarker deals 2007 to 2012
Figure 3: Bigpharma biomarker deal frequency – 2007 to 2012
Figure 4: Inactive bigpharma in biomarkers 2007-2012
Figure 5: Biomarker partnering by deal type since 2007
Figure 6: Biomarker partnering by disease type since 2007
Figure 7: Biomarker partnering by oncology target since 2007
Figure 8: Biomarker deals with a headline value
Figure 9: Biomarker deal headline value distribution, US$million – 2007-2012 – Discovery stage
Figure 10: Biomarker deal headline value distribution, US$million – 2007-2012 – preclinical stage
Figure 11: Biomarker deal headline value distribution, US$million – 2007-2012 – phase I stage
Figure 12: Biomarker deal headline value distribution, US$million – 2007-2012 – phase II stage
Figure 13: Biomarker deal headline value distribution, US$million – 2007-2012 – phase III stage
Figure 14: Biomarker deal headline value distribution, US$million – 2007-2012 – regulatory stage
Figure 15: Biomarker deal headline value distribution, US$million – 2007-2012 – marketed stage
Figure 16: Summary median headline value by stage of development, 2007-2012
Figure 17: Biomarker deals with an upfront value
Figure 18: Biomarker deal upfront value distribution, US$million – 2007-2012 – discovery stage
Figure 19: Biomarker deal upfront value distribution, US$million – 2007-2012 – preclinical stage
Figure 20: Biomarker deal upfront value distribution, US$million – 2007-2012 – phase I stage
Figure 21: Biomarker deal upfront value distribution, US$million – 2007-2012 – phase II stage
Figure 22: Biomarker deal upfront value distribution, US$million – 2007-2012 – phase III stage
Figure 23: Biomarker deal upfront value distribution, US$million – 2007-2012 – regulatory stage
Figure 24: Biomarker deal upfront value distribution, US$million – 2007-2012 – marketed stage
Figure 25: Summary median headline value by stage of development, 2007-2012
Figure 26: Biomarker deals with a milestone value
Figure 27: Biomarker deal milestone value distribution, US$million – 2007-2012 – discovery stage
Figure 28: Biomarker deal milestone value distribution, US$million – 2007-2012 – preclinical stage
Figure 29: Biomarker deal milestone value distribution, US$million – 2007-2012 – phase I stage
Figure 30: Biomarker deal milestone value distribution, US$million – 2007-2012 – phase II stage
Figure 31: Biomarker deal milestone value distribution, US$million – 2007-2012 – phase III stage
Figure 32: Biomarker deal milestone value distribution, US$million – 2007-2012 – regulatory stage
Figure 34: Biomarker deals with an upfront value
Figure 35: Biomarker deal royalty rate value distribution, US$million – 2007-2012 – discovery stage
Figure 36: Biomarker deal royalty rate value distribution, US$million – 2007-2012 – preclinical stage
Figure 37: Biomarker deal royalty rate value distribution, US$million – 2007-2012 – phase I stage
Figure 38: Biomarker deal royalty rate value distribution, US$million – 2007-2012 – phase II stage
Figure 39: Biomarker deal royalty rate value distribution, US$million – 2007-2012 – phase III stage
Figure 40: Biomarker deal royalty rate value distribution, US$million – 2007-2012 – regulatory stage
Figure 41: Biomarker deal royalty rate value distribution, US$million – 2007-2012 – marketed stage
Figure 42: Summary median headline value by stage of development, 2007-2012
Figure 43: Top biomarker deals by value since 2007
Figure 44: Top biomarker deals signed by bigpharma value since 2007
Figure 45: Partnering deals by cardiovascular therapy area since 2007
Figure 46: Partnering deals by CNS therapy area since 2007
Figure 47: Partnering deals by dental therapy area since 2007
Figure 48: Partnering deals by dermatology therapy area since 2007
Figure 49: Partnering deals by gastrointestinal therapy area since 2007
Figure 50: Partnering deals by genetic disorders therapy area since 2007
Figure 51: Partnering deals by genitourinary therapy area since 2007
Figure 52: Partnering deals by gynaecology therapy area since 2007
Figure 53: Partnering deals by hematology therapy area since 2007
Figure 54: Partnering deals by hospital care therapy area since 2007
Figure 55: Partnering deals by immunology therapy area since 2007
Figure 56: Partnering deals by infectives therapy area since 2007
Figure 57: Partnering deals by metabolic therapy area since 2007
Figure 58: Partnering deals by musculoskeletal therapy area since 2007
Figure 59: Partnering deals by obstetrics therapy area since 2007
Figure 60: Partnering deals by oncology therapy area since 2007
Figure 61: Partnering deals by ophthalmics therapy area since 2007
Figure 62: Partnering deals by pediatrics therapy area since 2007
Figure 63: Partnering deals by psychiatry therapy area since 2007
Figure 64: Partnering deals by public health therapy area since 2007
Figure 65: Partnering deals by respiratory therapy area since 2007
Figure 65: Partnering deals by respiratory therapy area since 2007
Figure 67: Online partnering resources
Figure 68: Forthcoming partnering events